Want to see ALDX full AI Analyst Report?
ALDX Stock Chart & Stats
$1.80
-$0.07(-1.37%)
At close: 4:00 PM EST
$1.80
-$0.07(-1.37%)
Day’s Range― - ―
52-Week Range$1.07 - $6.18
Previous CloseN/A
Volume102.94K
Average Volume (3M)1.75M
Market Cap
$101.94M
Enterprise Value$52.45
Total Cash (Recent Filing)$65.00M
Total Debt (Recent Filing)$15.51M
Price to Earnings (P/E)―
Beta2.69
Next Earnings
Jul 31, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding60,321,068
10 Day Avg. Volume1,664,156
30 Day Avg. Volume1,745,823
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)7.03
Price to Sales (P/S)0.00
P/FCF Ratio-9.33
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$2.00Price Target Upside11.11% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$1.25M
Bulls Say, Bears Say
Bulls Say
Platform Diversification (RASP-modulation)A shared RASP-modulation mechanism across multiple therapeutic areas provides durable optionality beyond a single indication. This platform approach enables repurposing of clinical assets, spreads development risk across programs, and increases long-term commercial pathways and partnering appeal.
Extended Cash Runway To 2028A communicated runway through 2028 materially reduces near-term financing pressure, allowing time for pivotal trials and regulatory interactions. Extended runway supports execution of development milestones and reduces immediate dilution risk, strengthening multi-quarter strategic planning.
Strengthened Governance And Financial OversightAdding an experienced, independent audit committee chair improves governance, financial reporting oversight and investor confidence. Strong board oversight is durable support during late-stage development and regulatory submissions, mitigating governance-related execution risk.
Bears Say
No Revenue / Persistent LossesThe company remains a pre-revenue biotech with consistent operating and net losses, meaning long-term value depends entirely on successful development and commercialization. Persistent losses erode equity, require future funding, and increase execution and financing risk over the medium term.
Volatile Cash Flow And Sustainability ConcernsHistoric cash burn with an atypical TTM improvement raises doubts about durability of cash generation. Reliance on a one-off or timing-driven cash improvement increases uncertainty around future runway and the company's ability to sustainably fund trials without additional capital.
Concentration Risk On Lead Candidate ReproxalapA heavy reliance on reproxalap for near- and medium-term value makes the company vulnerable to binary clinical or regulatory setbacks. Limited late-stage diversification raises the impact of any adverse outcome on the firm's ability to achieve commercial viability and justify continued investment.
Aldeyra Therapeutics News
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $1.07 and its highest was $6.17 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $101.94M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
Aldeyra Therapeutics’s upcoming earnings report date is Jul 31, 2026 which is in 10 days.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on May 07, 2026. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.098 by $0.038.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate is -0.08.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 60,321,068 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.098. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in ALDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aldeyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (11.11% Upside)
$2.00 (11.11% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $417.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 0.5%
Last 30 Days ▲ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-28.66%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
ALDX Stock 12 Month Forecast
Average Price Target
$2.00
▲(11.11% Upside)
Technical Analysis
Omeros
―
Galectin Therapeutics
―
Foghorn Therapeutics
―
Candel Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
3.66% Insiders
8.73% Mutual Funds
2.17% Other Institutional Investors
80.45% Public Companies and
Individual Investors